ArticleInfluenza and other respiratory viruses2026
Country-Level RSV-Related Hospitalisation Rates Among Adults in High-Income Countries From an Ensemble Model Based on Direct Viral Testing Incidence Data.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundUnderstanding hospitalisation burden of respiratory syncytial virus (RSV)-associated acute respiratory infection (ARI) in adults is crucial for informing immunisation policy, yet such data are lacking in most high-income countries. We aimed to estimate country-level RSV-associated ARI hospitalisation rates among adults aged 18-64 and ≥ 65 years across high-income countries.
methodsData on adult RSV hospitalisation burden were identified from systematic literature review and national surveillance reports. A Bayesian adjustment was applied to account for underascertainment due to variability in diagnostic methods and clinical specimens. An ensemble modelling framework consisting of four independent approaches was developed to predict country-level RSV-associated ARI hospitalisation rates among adults aged 18-64 and ≥ 65 years across 63 high-income countries.
resultsThe ensemble model predicted a median annual RSV-associated ARI hospitalisation rate of 39 per 100,000 (interquartile range [IQR]: 33-48) for adults aged 18-64 years and 374 per 100,000 (318-468) for those aged ≥ 65 years across the 63 countries. The predicted rates varied substantially by continent; Africa (Seychelles) had the lowest RSV hospitalisation rate for both 18-64 and ≥ 65 years (17 and 188 per 100,000, respectively); the highest median RSV hospitalisation rate was in Oceania in adults aged 18-64 years (50 per 100,000; IQR: 31-51) and was in the Americas in adults aged ≥ 65 years (455 per 100,000; 428-518). Europe and Asia showed marked within-continent variations in RSV hospitalisation rates.
conclusionsAlthough primary RSV disease burden data remain the gold standard for evidence-based vaccine policy development, this study offers a viable alternative reference for high-income countries lacking such data.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.